Inactive Instrument

Press Releases NeoStem Inc Nyse

Equities

NBS

US6406503051

End-of-day quote Nyse Other stock markets
- ^USD	-

May. 20	Sector Update: Health Care Stocks Softer Late Afternoon	MT
May. 20	Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events	May. 28	GL
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer	May. 20	GL
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results	May. 13	AQ
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	May. 09	GL
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	May. 08	GL
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	May. 08	AQ
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	May. 02	GL
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	May. 02	AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 24	AQ
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	Apr. 23	AQ
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	Apr. 23	GL
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Apr. 09	GL
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	Apr. 03	GL
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	Mar. 21	GL
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	Mar. 04	AQ
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	Feb. 29	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	GL
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	Feb. 22	AQ
Lisata Therapeutics to Present at BIO CEO & Investor Conference	Feb. 20	GL
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	Jan. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NeoStem Inc Nyse

Equities

NBS

US6406503051

Press Releases

Filters